2022
Deprescription of aspirin for primary prevention is uncommon at discharge in hospitalised patients with gastrointestinal bleeding
Li D, Ong S, Hughes M, Hung K, Agarwal R, Alexis J, Damianos J, Sharma S, Pires J, Nanna M, Laine L. Deprescription of aspirin for primary prevention is uncommon at discharge in hospitalised patients with gastrointestinal bleeding. Alimentary Pharmacology & Therapeutics 2022, 57: 94-102. PMID: 36394111, DOI: 10.1111/apt.17278.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsGastrointestinal bleedingPrimary preventionCardiovascular eventsRisk of MACEYale-New Haven HospitalPrimary cardiovascular preventionAdverse cardiovascular eventsKaplan-Meier curvesLong-term outcomesRisk-benefit ratioLog-rank testAspirin 81Hospitalised patientsPrimary endpointSecondary endpointsCardiovascular preventionSubsequent hospitalisationMedian ageDeprescriptionHigh riskAspirinHospitalisationPatientsPrevention
2020
Estimating Aspirin Overuse for Primary Prevention of Atherosclerotic Cardiovascular Disease (from a Nationwide Healthcare System)
Ong SY, Chui P, Bhargava A, Justice A, Hauser RG. Estimating Aspirin Overuse for Primary Prevention of Atherosclerotic Cardiovascular Disease (from a Nationwide Healthcare System). The American Journal Of Cardiology 2020, 137: 25-30. PMID: 32991852, DOI: 10.1016/j.amjcard.2020.09.042.Peer-Reviewed Original ResearchConceptsLow-dose aspirinElectronic health recordsSelf-reported useEHR dataPatients' self-reported useLow-dose aspirin useAtherosclerotic cardiovascular diseaseAmerican Heart AssociationEHR recordsNon-specific terminologyAspirin usePrimary preventionHeart AssociationCardiovascular diseaseAmerican CollegeAspirinPatientsHealth recordsEHR implementationEHR searchesImplementable guidelinesGuidelinesRecordsDiseaseCardiology
2015
Prostate Cancer‐Associated Disseminated Intravascular Coagulation with Excessive Fibrinolysis Treated with Degarelix
Ong SY, Taverna J, Jokerst C, Enzler T, Hammode E, Rogowitz E, Green MR, Babiker HM. Prostate Cancer‐Associated Disseminated Intravascular Coagulation with Excessive Fibrinolysis Treated with Degarelix. Case Reports In Oncological Medicine 2015, 2015: 212543. PMID: 26613055, PMCID: PMC4646996, DOI: 10.1155/2015/212543.Peer-Reviewed Original ResearchDisseminated intravascular coagulationProstate cancerIntravascular coagulationExcessive fibrinolysisGonadotropin-releasing hormone receptor antagonistTherapeutic drug optionsHormone receptor antagonistLife-threatening variantDays of treatmentHemorrhagic complicationsSystemic bleedingDrug optionsReceptor antagonistPatient's coagulopathySingle injectionCoagulopathyDegarelixPatientsFibrinolysisCancerCoagulationBleedingComplicationsAntagonistHypofibrinogenemia